AGS is a biotech company developing innovative biomedicines based on extracellular vesicles from microalgae (MEV), a new kind of safe, targeted and highly versatile delivery system for therapeutic molecules from natural and synthetic biology designed to address a wide range of diseases.

Widespread use of innovative biologics -RNA, DNA, proteins, gene editing complexes, and gene expression plasmids - for the treatment of human diseases remains elusive due to the lack of an effective drug delivery system (DDS). The inability to deliver therapeutic doses to the right target in the body without affecting other organs or tissues or to overcome natural barriers – brain blood barrier or gut – has been a significant bottleneck in unleashing the power of the most advanced biologics as effective biomedicines for patients.